Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART)

Clinical Endocrinology

Volumn 76, Issue 5, 2012, Pages 643-648

  Bolland, Mark J ^a   Grey, Andrew ^a   Horne, Anne M ^a   Briggs, Simon E ^a   Thomas, Mark G ^a   Ellis Pegler, Rod B ^a   Gamble, Greg D ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LUMBAR SPINE; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 84859645792     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04274.x     Document Type: Article

References (24)

1. Nolan, D., Upton, R., McKinnon, E. et al. (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. Acquired Immune Deficiency Syndrome, 15, 1275-1280. (Pubitemid 32592360)
2. Mondy, K., Yarasheski, K., Powderly, W.G. et al. (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical Infectious Diseases, 36, 482-490. (Pubitemid 36241317)
3. Dolan, S.E., Kanter, J.R. & Grinspoon, S. (2006) Longitudinal analysis of bone density in human immunodeficiency virus-infected women. Journal of Clinical Endocrinology and Metabolism, 91, 2938-2945. (Pubitemid 44271739)
4. Bolland, M.J., Grey, A.B., Horne, A.M. et al. (2007) Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clinical Endocrinology, 67, 270-275. (Pubitemid 47076305)
5. Sharma, A., Flom, P.L., Weedon, J. et al. (2010) Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. Acquired Immune Deficiency Syndrome, 24, 2337-2345.
6. Gallant, J.E., Staszewski, S., Pozniak, A.L. et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in anti-retroviral- naive patients: a 3-year randomized trial. JAMA, 292, 191-201. (Pubitemid 38917996)
7. Duvivier, C., Kolta, S., Assoumou, L. et al. (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Acquired Immune Deficiency Syndrome, 27, 817-824.
8. van Vonderen, M.G., Lips, P., van Agtmael, M.A. et al. (2009) First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. Acquired Immune Deficiency Syndrome, 23, 1367-1376.
9. Stellbrink, H.J., Orkin, C., Arribas, J.R. et al. (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical Infectious Diseases, 51, 963-972.
10. Hansen, A., Obel, N., Nielsen, H. et al. (2011) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Medicine, 12, 157-165.
11. Bolland, M.J., Wang, T.K., Grey, A. et al. (2011) Stable bone density in HAART-treated individuals with HIV: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 96, 2721-2731.
12. Bolland, M.J., Grey, A.B., Horne, A.M. et al. (2008) Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. Journal of Bone and Mineral Research, 23, 1304-1308. (Pubitemid 352040185)
13. Bolland, M.J., Grey, A.B., Horne, A.M. et al. (2007) Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism, 92, 1283-1288. (Pubitemid 46556399)
14. Bolland, M.J., Grey, A.B., Horne, A.M. et al. (2006) Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clinical Endocrinology, 65, 191-197. (Pubitemid 44079682)
15. Cassetti, I., Madruga, J.V., Suleiman, J.M. et al. (2007) The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clinical Trials, 8, 164-172. (Pubitemid 47121761)
16. Bolland, M.J., Grey, A.B., Gamble, G.D. et al. (2007) Low body weight mediates the relationship between HIV Infection and low bone mineral density: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 92, 4522-4528. (Pubitemid 350223420)
17. Aukrust, P., Haug, C.J., Ueland, T. et al. (1999) Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism, 84, 145-150. (Pubitemid 29036693)
18. Amiel, C., Ostertag, A., Slama, L. et al. (2004) BMD is reduced in HIV-infected men irrespective of treatment. Journal of Bone and Mineral Research, 19, 402-409. (Pubitemid 38787395)
19. Hotta, M., Fukuda, I., Sato, K. et al. (2000) The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism, 85, 200-206. (Pubitemid 32268814)
20. Zipfel, S., Seibel, M.J., Lowe, B. et al. (2001) Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. Journal of Clinical Endocrinology and Metabolism, 86, 5227-5233. (Pubitemid 33070240)
21. Hall, G.M., Spector, T.D. & Delmas, P.D. (1995) Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. Arthritis and Rheumatism, 38, 902-906.
22. Redlich, K., Ziegler, S., Kiener, H.P. et al. (2000) Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 59, 308-310. (Pubitemid 30305576)
23. Borderi, M., Gibellini, D., Vescini, F. et al. (2009) Metabolic bone disease in HIV infection. Acquired Immune Deficiency Syndrome, 23, 1297-1310.
24. McComsey, G.A., Tebas, P., Shane, E. et al. (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clinical Infectious Diseases, 51, 937-946.